CDIO Key Statistics, Chart & Performance
The current stock price of CDIO is 3.33 USD. In the past month the price increased by 13.27%. In the past year, price decreased by -88%.
CDIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About CDIO
Company Profile
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Company Info
CARDIO DIAGNOSTICS HOLDINGS
311 W. Superior Street, Suite 444
Chicago ILLINOIS US
Employees: 13
Phone: 18552269991
CARDIO DIAGNOSTICS HOLDINGS / CDIO FAQ
What does CDIO do?
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Can you provide the latest stock price for CARDIO DIAGNOSTICS HOLDINGS?
The current stock price of CDIO is 3.33 USD. The price decreased by -2.63% in the last trading session.
Does CARDIO DIAGNOSTICS HOLDINGS pay dividends?
CDIO does not pay a dividend.
What is the ChartMill rating of CARDIO DIAGNOSTICS HOLDINGS stock?
CDIO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for CARDIO DIAGNOSTICS HOLDINGS?
CARDIO DIAGNOSTICS HOLDINGS (CDIO) currently has 13 employees.
What is the market capitalization of CDIO stock?
CARDIO DIAGNOSTICS HOLDINGS (CDIO) has a market capitalization of 6.09M USD. This makes CDIO a Nano Cap stock.
Can you provide the upcoming earnings date for CARDIO DIAGNOSTICS HOLDINGS?
CARDIO DIAGNOSTICS HOLDINGS (CDIO) will report earnings on 2026-03-18.
CDIO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CDIO. When comparing the yearly performance of all stocks, CDIO is a bad performer in the overall market: 95.02% of all stocks are doing better.
CDIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CDIO. While CDIO has a great health rating, there are worries on its profitability.
CDIO Financial Highlights
Over the last trailing twelve months CDIO reported a non-GAAP Earnings per Share(EPS) of -9.9. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.55% | ||
| ROE | -80.38% | ||
| Debt/Equity | 0 |
CDIO Forecast & Estimates
7 analysts have analysed CDIO and the average price target is 61.2 USD. This implies a price increase of 1737.84% is expected in the next year compared to the current price of 3.33.
For the next year, analysts expect an EPS growth of 22.73% and a revenue growth 854.55% for CDIO